Biotech Values

[DewDiligence]

>It's amazing that Avastin is still killing erbitux in 2nd line with little data (mostly negative)<

What’s somewhat disappointing about the Erbitux CRC numbers is that all growth is coming from market expansion rather increased penetration. It’s not so much that Avastin is killing Erbitux but rather that a lot of patients in the second- and third-line settings continue to get chemo only (or nothing at all).